Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Rust, Steven ^a   Guillard, Sandrine ^a   Sachsenmeier, Kris ^a   Hay, Carl ^a   Davidson, Max ^b   Karlsson, Anders ^b   Karlsson, Roger ^b   Brand, Erin ^a   Lowne, David ^a   Elvin, John ^a   Flynn, Matt ^a   Kurosawa, Gene ^c   Hollingsworth, Robert ^a   Jermutus, Lutz ^a   Minter, Ralph ^a  

^a MEDIMMUNE   (United States)

^b NANOXIS CONSULTING AB   (Sweden)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Antibody; CD73; Hybridoma; Membranome; Phage display; Phenotypic screening

Indexed keywords

5' NUCLEOTIDASE; CD71 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; GALECTIN 3; HERMES ANTIGEN;

ANTIBODY SCREENING; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL MEMBRANE; CELL SPECIFICITY; CELL TYPE; CONTROLLED STUDY; MASS SPECTROMETRY; PROTEIN ANALYSIS; PROTEOMICS; TRIPLE NEGATIVE BREAST CANCER;

5'-NUCLEOTIDASE; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYBRIDOMAS; MEMBRANE PROTEINS; MICE; MICE, NUDE; PEPTIDE LIBRARY; PHENOTYPE; PROTEIN BINDING; PROTEOME; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RIBOSOME INACTIVATING PROTEINS, TYPE 1; SINGLE-CHAIN ANTIBODIES; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874283227     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-11     Document Type: Article

References (22)

1. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007, 6:349-356. 10.1038/nrd2241, 17431406.
2. Song J, Yang W, Shih I, Zhang Z, Bai J. Identification of BCOX1, a novel gene overexpressed in breast cancer. Biochim Biophys Acta 2006, 1760:62-69. 10.1016/j.bbagen.2005.09.017, 16289875.
3. Suzuki A, Iizuka A, Komiyama M, Takikawa M, Kume A, Tai S, Ohshita C, Kurusu A, Nakamura Y, Yamamoto A, Yamazaki N, Yoshikawa S, Kiyohara Y, Akiyama Y. Identification of melanoma antigens using a Serological Proteome Approach (SERPA). Cancer Genomics Proteomics 2010, 7:17-23.
4. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 2004, 11:659-687. 10.1677/erc.1.00766, 15613445.
5. Sachsenmeier KF, Terrett JA. Image-Based Assays of Cellular Phenotype for Drug Target discovery and Validation. The Oncogenomics Handbook 2005, Totowa, New Jersey: Humana Press, LaRochelle WJ, Shimkets RA.
6. Swinney DC, Anthony J. How were new medicines discovered?. Nat Rev Drug Discov 2011, 10:507-519. 10.1038/nrd3480, 21701501.
7. Kurosawa G, Akahori Y, Morita M, Sumitomo M, Sato N, Muramatsu C, Eguchi K, Matsuda K, Takasaki A, Tanaka M, Iba Y, Hamada-Tsutsumi S, Ukai Y, Shiraishi M, Suzuki K, Kurosawa M, Fujiyama S, Takahashi N, Kato R, Mizoguchi Y, Shamoto M, Tsuda H, Sugiura M, Hattori Y, Miyakawa S, Shiroki R, Hoshinaga K, Hayashi N, Sugioka A, Kurosawa Y. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. P Natl Acad Sci USA 2008, 105:7287-7292.
8. Cailleau R, Young R, Olive M, Reeves WJ. Breast tumor cell lines from pleural effusions. J Natl Cancer Inst 1974, 53:661-674.
9. Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 2011, 125:627-636. 10.1007/s10549-010-1293-1, 3244802, 21161370.
10. Sachsenmeier KF, Hay C, Brand E, Clarke L, Rosenthal K, Guillard S, Rust S, Minter R, Hollingsworth R. Development of a Novel Ectonucleotidase Assay Suitable for High-Throughput Screening. J Biomol Screen 2012, 72:2176-2182.
11. Ahram M, Litou ZI, Fang R, Al-Tawallbeh G. Estimation of membrane proteins in the human proteome. In Silico Biol 2006, 6:379-386.
12. Seetharaman J, Kanigsberg A, Slaaby R, Leffler H, Barondes SH, Rini JM. X-ray Crystal Structure of the Human Galectin-3 Carbohydrate Recognition Domain at 2.1-Å Resolution. J Biol Chem 1998, 273:13047-13052. 10.1074/jbc.273.21.13047, 9582341.
13. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakraverthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011, 121:2750-2767. 10.1172/JCI45014, 3127435, 21633166.
14. Lo Nigro C, Monteverde M, Lee S, Lattanzio L, Vivenza D, Comino A, Syed N, McHugh A, Wang H, Proby C, Garrone O, Merlano M, Hatzimichael E, Briasoulis E, Gojis O, Palmieri C, Jordan L, Quinlan P, Thompson A, Crook T. NT5E CpG island methylation is a favourable breast cancer biomarker. Br J Cancer 2012, 107:75-83. 10.1038/bjc.2012.212, 22653144.
15. Zahnd C, Pecorari F, Straumann N, Wyler E, Pluckthun A. Selection and charcterisation of Her2 binding-designed ankyrin repeat proteins. J Biol Chem 2006, 281:35167-35175. 10.1074/jbc.M602547200, 16963452.
16. Kruger KH, Thompson LF, Kaufmann M, Moller P. Expression of ecto-5'-nucleotidase (CD73) in normal mammary gland and in breast carcinoma. Brit J Cancer 1991, 63:114-118. 10.1038/bjc.1991.23, 1971649, 1989648.
17. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. P Natl Acad Sci USA 2010, 107:1547-1552.
18. Padliya ND, Bhatia MB, Hofgartner WT, Hariri RJ. Improving the depth of coverage in membrane proteomic studies through the use of lipid-based protein immobilization technology in parallel with methanol-facilitated solubilisation. Anal Methods 2009, 2:539-545.
19. Lloyd C, Lowe D, Edwards B, Welsh F, Dilks T, Hardman C, Vaughan T. Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 2009, 22:159-168.
20. Vaughan TJ, Williams AJ, Pritchard K, Osbourn JK, Pope AR, Earnshaw JC, McCafferty J, Hodits RA, Wilton J, Johnson KS. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnol 1996, 14:309-314.
21. Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Caterson B, McIntyre GD. Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 1997, 16:381-389. 10.1089/hyb.1997.16.381, 9309429.
22. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495-497. 10.1038/256495a0, 1172191.